WVE: Wave Life Sciences Ltd. Stock

by  •  • Comments Off on WVE: Wave Life Sciences Ltd. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1,718.90
Enterprise Value ($M) 1,415.82
Book Value ($M) 149.51
Book Value / Share 0.98
Price / Book 11.50
NCAV ($M) 115.53
NCAV / Share 0.76
Price / NCAV 14.88

Profitability (mra)
Return on Invested Capital (ROIC) -0.81
Return on Assets (ROA) -0.52
Return on Equity (ROE) -3.00

Liquidity (mrq)
Quick Ratio 1.90
Current Ratio 1.90

Balance Sheet (mrq) ($M)
Current Assets 324.51
Assets 358.50
Liabilities 208.99
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-12 13G/A Adage Capital Management, L.P. 6.66
11-12 13G/A M28 Capital Management LP 4.20 -16.39
11-12 13G/A Glaxosmithkline Plc 11.20 19.97
11-08 13G BlackRock, Inc. 5.00 0.00
10-01 13D/A Ra Capital Management, L.p. 16.00 47.16
02-14 13G/A 683 Capital Management, LLC 4.70 -6.67
02-14 13G/A Maverick Capital Ltd 6.90 19.02
02-13 13G/A Bb Biotech Ag 3.70 0.00
02-07 13G/A Adage Capital Partners Gp, L.l.c. 5.03 8.34

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-04-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ T
2024-03-06 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-14 279,205 958,095 29.14
2025-01-13 154,509 1,173,725 13.16
2025-01-10 343,105 1,431,248 23.97

(click for more detail)

Similar Companies
VERA – Vera Therapeutics, Inc. VNDA – Vanda Pharmaceuticals Inc.
VRCA – Verrica Pharmaceuticals Inc. XENE – Xenon Pharmaceuticals Inc.
XNCR – Xencor, Inc.


Financial data and stock pages provided by
Fintel.io